MX2025001965A - Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer - Google Patents

Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer

Info

Publication number
MX2025001965A
MX2025001965A MX2025001965A MX2025001965A MX2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A
Authority
MX
Mexico
Prior art keywords
mta
treatment
cooperative
cancer
prmt5 inhibitors
Prior art date
Application number
MX2025001965A
Other languages
English (en)
Inventor
James Thomas Lynch
Ho Man Chan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2025001965A publication Critical patent/MX2025001965A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02028—S-Methyl-5'-thioadenosine phosphorylase (2.4.2.28)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente memoria descriptiva se refiere a métodos de tratamiento de cánceres con el gen MTAP natural que comprenden administrar un inhibidor de PRMT5 sinérgico con MTA a un paciente que lo necesita.
MX2025001965A 2022-08-15 2025-02-17 Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer MX2025001965A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263397996P 2022-08-15 2022-08-15
PCT/EP2023/072364 WO2024038004A1 (en) 2022-08-15 2023-08-14 Mta-cooperative prmt5 inhibitors for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2025001965A true MX2025001965A (es) 2025-04-02

Family

ID=87748037

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001965A MX2025001965A (es) 2022-08-15 2025-02-17 Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer

Country Status (11)

Country Link
US (1) US20260048040A1 (es)
EP (1) EP4572760A1 (es)
JP (1) JP2025528186A (es)
KR (1) KR20250048049A (es)
CN (1) CN119730853A (es)
AU (1) AU2023327684A1 (es)
CA (1) CA3263923A1 (es)
IL (1) IL318816A (es)
MX (1) MX2025001965A (es)
TW (1) TW202423435A (es)
WO (1) WO2024038004A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2026114356A1 (zh) * 2024-11-29 2026-06-04 普罗思特(南京)生物科技有限公司 含氮杂环化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3160958T3 (da) 2014-06-25 2021-04-12 Glaxosmithkline Ip Dev Ltd Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid
CN120208880A (zh) * 2019-09-12 2025-06-27 米拉蒂医疗股份有限公司 Mta-协同prmt5抑制剂
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
MX2022010011A (es) 2020-02-12 2022-10-18 Amgen Inc Inhibidores de prmt5 novedosos.
CN116568677B (zh) 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
EP4251624B1 (en) 2020-11-24 2025-10-29 Amgen Inc. Tricyclic carboxamide derivatives as prmt5 inhibitors
LT4263545T (lt) 2020-12-16 2026-07-27 Amgen Inc. Prmt5 inhibitoriai
RU2757957C1 (ru) 2020-12-30 2021-10-25 Александр Григорьевич ВИЛЛЕР Роботизированная система и способ проведения эндоваскулярной хирургической операции
CN117062816A (zh) 2021-02-04 2023-11-14 美国安进公司 三环-酰胺-双环prmt5抑制剂
EP4304720A1 (en) 2021-03-11 2024-01-17 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
US20240368153A1 (en) 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
EP4402143A1 (en) 2021-09-13 2024-07-24 Astrazeneca AB Spirocyclic compounds
KR20240157631A (ko) 2021-11-05 2024-11-01 미라티 테라퓨틱스, 인크. Prmt5 저해제로서 2-아미노 이미다졸 유도체
EP4442680A4 (en) 2021-11-30 2026-05-06 Abbisko Therapeutics Co Ltd Pyrazole derivative, its preparation process and its use in medicine
CN116462677A (zh) 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
CN116462676A (zh) 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
CN116178347B (zh) 2022-06-29 2025-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂

Also Published As

Publication number Publication date
AU2023327684A1 (en) 2025-03-20
US20260048040A1 (en) 2026-02-19
EP4572760A1 (en) 2025-06-25
KR20250048049A (ko) 2025-04-07
CA3263923A1 (en) 2024-02-22
JP2025528186A (ja) 2025-08-26
WO2024038004A1 (en) 2024-02-22
IL318816A (en) 2025-04-01
TW202423435A (zh) 2024-06-16
CN119730853A (zh) 2025-03-28

Similar Documents

Publication Publication Date Title
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
JOP20250258A1 (ar) مثبطات 2-آزا باي سيكلو هبتان kras
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
MX2024009727A (es) Terapias de combinacion.
MX2025003821A (es) Compuestos con actividad contra tumores mutantes de kras
MX2022009347A (es) Terapia de combinacion para el tratamiento del crecimiento celular anormal.
SA522431915B1 (ar) Prmt5 مثبطات mta تعاونية مع
PH12022552739A1 (en) Fused tricyclic kras inhibitors
WO2021243280A3 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
Shah et al. Granulomatous slack skin disease: a review, in comparison with mycosis fungoides
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
WO2020205473A8 (en) Compositions and methods for the treatment of kras associated diseases or disorders
CR20210409A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
MX2023011856A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
MY183661A (en) Treatment of cancer with tor kinase inhibitors
EP4389225A3 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
MX2009007777A (es) Terapia de combinacion que comprende romidepsina y bortezomib.
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
MX2025003908A (es) Compuesto inhibidor de parg
JOP20250150A1 (ar) علاجات السرطان باستخدام مثبطات prmt5 التعاونية مع mta
MX2025014397A (es) Inhibidores de helicasa de adn recq del sindrome de werner (wrn)